<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083729</url>
  </required_header>
  <id_info>
    <org_study_id>PH after mitral commissurtomy</org_study_id>
    <nct_id>NCT04083729</nct_id>
  </id_info>
  <brief_title>Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy</brief_title>
  <official_title>Predictors of Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy and Its Impact on Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify clinical, echocardiographic, and hemodynamic parameters which can predict
      persistent PH after PMC, and also to determine the impact of persistent PH on the clinical
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pure mitral Stenosis develops in approximately 40% of all patients with rheumatic heart
      disease, and is frequently complicated by Pulmonary hypertension (PH). Pulmonary hypertension
      influences symptomatology and long-term prognosis. Percutaneous Mitral Commissurotomy (PMC),
      was first described in 1984, has good results and is performed by antegrade access to the
      mitral valve through trans-septal puncture by one of various techniques (e.g. Inuoe, and
      multitrack system). Pulmonary artery pressures (PAP) decrease following PMC. The improvement
      in pulmonary hypertension after PMC is explained by the improvement in the mitral valve area
      and subsequent decompression of left atrium (LA) and pulmonary venous beds. Even though there
      have been studies showing excellent results following PMC in all grades of PH, nonregression
      of PH following PMC is not uncommon. The component of PAP contributed by the passive
      transmission of the elevated LA pressure regresses immediately after a successful PMC
      proportional to the reduction in transmitral gradient. The PH contributed by pulmonary
      arteriolar constriction slowly comes down over weeks or a few months, But a &quot;fixed&quot; component
      due to pulmonary vascular disease usually persists.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>predictors of Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>percutaneous mitral commissurotomy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of cardiovascular event</measure>
    <time_frame>Participants will be followed for a minimum follow-up of one month</time_frame>
    <description>Composite of cardiovascular mortality, cerebral infarction, systemic embolic events ,RV failure ,MV re stenosis that occurred during follow-up, and PMC-related complications; procedural mortality and urgent MV surgery. parameters changes from base line study and after follow up as MVA in cm 2,PASP in mmHg,LAP in mmHg,LVEP in mmHg,PVR in wood unit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with persistent pulmonary hypertension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without persistent pulmonary hypertension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Mitral Commissurotomy</intervention_name>
    <description>Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area &gt; 1.5 square cm with less than moderate to severe mitral regurgitation.</description>
    <arm_group_label>Patients with persistent pulmonary hypertension</arm_group_label>
    <arm_group_label>Patients without persistent pulmonary hypertension</arm_group_label>
    <other_name>Percutaneous mitral valvuloplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe mitral stenosis (mitral valve area ≤1.5cm).

          -  Significant dyspnea.

          -  Favorable anatomical characteristics for PMC as assessed by transthoracic
             echocardiography

        Exclusion Criteria:

          -  Significant mitral regurgitation (≥ grade II/IV). Bilateral commissural calcification.

          -  Presence of other lesions which need open heart surgery.

          -  Wilkins' score &gt; 12.

          -  Persistent LA thrombus despite adequate anticoagulation.

          -  End stage renal or liver disease.

          -  Patients with severe COPD and other chest problems that might be complicated by
             pulmonary hypertension per se.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed Abdelghany Koreim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University, 71515 Assiut, Egypt.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hosam Hasan El Araby</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University, 71515 Assiut, Egypt.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr ElBadry Ibrahim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University, 71515 Assiut, Egypt.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed abdelfatah Ahmed</last_name>
    <phone>+2001121560152</phone>
    <email>drmohamedabdelfatah@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amr Elbadry ibrahim</last_name>
    <phone>+2001060701601</phone>
    <email>aelbadry@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Hart SA, Krasuski RA, Wang A, Kisslo K, Harrison JK, Bashore TM. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis. 2010 Nov;19(6):708-15.</citation>
    <PMID>21214093</PMID>
  </reference>
  <reference>
    <citation>Noor A, Saghir T, Zaman KS. Determinants of decrease in pulmonary hypertension following percutaneous transvenous mitral commissurotomy. J Coll Physicians Surg Pak. 2009 Feb;19(2):81-5. doi: 02.2009/JCPSP.8185.</citation>
    <PMID>19208309</PMID>
  </reference>
  <reference>
    <citation>Bahl VK, Chandra S, Talwar KK, Kaul U, Sharma S, Wasir HS. Balloon mitral valvotomy in patients with systemic and suprasystemic pulmonary artery pressures. Cathet Cardiovasc Diagn. 1995 Nov;36(3):211-5.</citation>
    <PMID>8542626</PMID>
  </reference>
  <reference>
    <citation>Fawzy ME, Osman A, Nambiar V, Nowayhed O, El DA, Badr A, Canver CC. Immediate and long-term results of mitral balloon valvuloplasty in patients with severe pulmonary hypertension. J Heart Valve Dis. 2008 Sep;17(5):485-91.</citation>
    <PMID>18980082</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed Abdel Fattah Mohamed Ahmed</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

